JP2019516663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516663A5 JP2019516663A5 JP2018543337A JP2018543337A JP2019516663A5 JP 2019516663 A5 JP2019516663 A5 JP 2019516663A5 JP 2018543337 A JP2018543337 A JP 2018543337A JP 2018543337 A JP2018543337 A JP 2018543337A JP 2019516663 A5 JP2019516663 A5 JP 2019516663A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- fragment
- cancer
- antibody
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086571A JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
| JP2022206084A JP7564183B2 (ja) | 2016-03-01 | 2022-12-22 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
| JP2024167901A JP2025011134A (ja) | 2016-03-01 | 2024-09-26 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302010P | 2016-03-01 | 2016-03-01 | |
| GBGB1603568.5A GB201603568D0 (en) | 2016-03-01 | 2016-03-01 | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| US62/302,010 | 2016-03-01 | ||
| GB1603568.5 | 2016-03-01 | ||
| PCT/EP2017/054559 WO2017148888A1 (en) | 2016-03-01 | 2017-02-28 | Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086571A Division JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516663A JP2019516663A (ja) | 2019-06-20 |
| JP2019516663A5 true JP2019516663A5 (enExample) | 2020-04-09 |
Family
ID=55807140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543337A Pending JP2019516663A (ja) | 2016-03-01 | 2017-02-28 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
| JP2021086571A Active JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086571A Active JP7201740B2 (ja) | 2016-03-01 | 2021-05-23 | 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10400011B2 (enExample) |
| EP (2) | EP3423085A1 (enExample) |
| JP (2) | JP2019516663A (enExample) |
| KR (1) | KR20180118702A (enExample) |
| CN (1) | CN109152825A (enExample) |
| AU (2) | AU2017227967B2 (enExample) |
| BR (1) | BR112018016734A2 (enExample) |
| CA (1) | CA3014848A1 (enExample) |
| CO (1) | CO2018008763A2 (enExample) |
| CR (4) | CR20210035A (enExample) |
| EA (1) | EA201891670A1 (enExample) |
| GB (1) | GB201603568D0 (enExample) |
| IL (1) | IL261266B2 (enExample) |
| MA (2) | MA43090A1 (enExample) |
| MX (1) | MX2018010167A (enExample) |
| SG (3) | SG10202008107QA (enExample) |
| TW (1) | TWI641617B (enExample) |
| WO (1) | WO2017148888A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| BR112019013402A2 (pt) | 2016-12-28 | 2020-03-03 | Invvax, Inc. | Vacinas de influenza |
| CN118370809A (zh) | 2017-04-03 | 2024-07-23 | 百欧恩泰美国公司 | 蛋白质抗原及其用途 |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| CA3083242A1 (en) * | 2017-11-21 | 2019-05-31 | Naofumi MIWA | Human cancer cell metastasis inhibitory agent and human cancer cell determination agent |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| WO2019126186A1 (en) | 2017-12-18 | 2019-06-27 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| CA3097399A1 (en) | 2018-04-19 | 2019-10-24 | The Board Of Regents, The University Of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| EP3810182A4 (en) | 2018-06-19 | 2022-08-24 | BioNTech US Inc. | Neoantigens and uses thereof |
| CN109801270B (zh) | 2018-12-29 | 2021-07-16 | 北京市商汤科技开发有限公司 | 锚点确定方法及装置、电子设备和存储介质 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PH12021552979A1 (en) | 2019-05-27 | 2023-10-09 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
| CN114303060A (zh) | 2019-06-06 | 2022-04-08 | 伊玛提克斯生物技术有限公司 | 使用序列相似肽进行反向选择分选 |
| KR20220062488A (ko) * | 2019-06-12 | 2022-05-17 | 바이오엔테크 유에스 인크. | 신생항원 조성물 및 이의 용도 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| CN111118011B (zh) * | 2020-02-11 | 2022-09-06 | 昆明医科大学 | 一种抑制hsa_circ_0027478表达的siRNA及其应用 |
| IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for propagating t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN116333999A (zh) * | 2020-07-14 | 2023-06-27 | 广州泛恩生物科技有限公司 | 基于cxcl13阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用 |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| WO2022147029A2 (en) | 2020-12-31 | 2022-07-07 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| US12319720B2 (en) * | 2021-08-31 | 2025-06-03 | Washington University | Neoantigen vaccines for triple negative breast cancer |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| AU2023262596A1 (en) | 2022-04-28 | 2024-12-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN115785206B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标07及其用途 |
| CN115961032A (zh) * | 2022-09-19 | 2023-04-14 | 深圳市罗湖区人民医院 | 一种膀胱癌相关突变基因的检测探针、检测试剂盒、突变质控品 |
| WO2025021979A1 (en) | 2023-07-27 | 2025-01-30 | Immatics Biotechnologies Gmbh | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| TW202506719A (zh) | 2023-07-27 | 2025-02-16 | 德商艾瑪提克生物技術有限公司 | 針對mageb2之抗原結合蛋白 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026033136A1 (en) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Advanced treatment modalities for anti-prame tcr-engineered immune cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005527180A (ja) * | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス， インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
| US20070073047A1 (en) | 2002-06-10 | 2007-03-29 | Biogen Idec Ma Inc. | Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| ATE461215T1 (de) * | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| KR100906145B1 (ko) * | 2006-05-30 | 2009-07-03 | 한국생명공학연구원 | Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제 |
| JP4546578B2 (ja) * | 2006-07-05 | 2010-09-15 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | プロテアーゼスクリーニング方法およびそれにより同定されるプロテアーゼ |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| TW201124530A (en) * | 2009-12-01 | 2011-07-16 | Oncotherapy Science Inc | IMP-3 oligopeptides and vaccines including the same |
| EP2336771A1 (en) * | 2009-12-16 | 2011-06-22 | Universität Duisburg-Essen | HAS3v2 as tumor marker |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201511792D0 (en) * | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
-
2016
- 2016-03-01 GB GBGB1603568.5A patent/GB201603568D0/en not_active Ceased
-
2017
- 2017-02-28 SG SG10202008107QA patent/SG10202008107QA/en unknown
- 2017-02-28 JP JP2018543337A patent/JP2019516663A/ja active Pending
- 2017-02-28 EP EP17707843.3A patent/EP3423085A1/en not_active Withdrawn
- 2017-02-28 KR KR1020187027578A patent/KR20180118702A/ko not_active Ceased
- 2017-02-28 CR CR20210035A patent/CR20210035A/es unknown
- 2017-02-28 CR CR20180398A patent/CR20180398A/es unknown
- 2017-02-28 BR BR112018016734A patent/BR112018016734A2/pt not_active Application Discontinuation
- 2017-02-28 CA CA3014848A patent/CA3014848A1/en active Pending
- 2017-02-28 SG SG10202110228Y patent/SG10202110228YA/en unknown
- 2017-02-28 MA MA43090A patent/MA43090A1/fr unknown
- 2017-02-28 CN CN201780014493.6A patent/CN109152825A/zh active Pending
- 2017-02-28 WO PCT/EP2017/054559 patent/WO2017148888A1/en not_active Ceased
- 2017-02-28 IL IL261266A patent/IL261266B2/en unknown
- 2017-02-28 AU AU2017227967A patent/AU2017227967B2/en not_active Expired - Fee Related
- 2017-02-28 MX MX2018010167A patent/MX2018010167A/es unknown
- 2017-02-28 EP EP21171324.3A patent/EP3915577A1/en active Pending
- 2017-02-28 CR CR20210033A patent/CR20210033A/es unknown
- 2017-02-28 US US15/445,461 patent/US10400011B2/en active Active
- 2017-02-28 CR CR20210034A patent/CR20210034A/es unknown
- 2017-02-28 SG SG11201806951TA patent/SG11201806951TA/en unknown
- 2017-02-28 EA EA201891670A patent/EA201891670A1/ru unknown
- 2017-02-28 MA MA043690A patent/MA43690A/fr unknown
- 2017-03-01 TW TW106106638A patent/TWI641617B/zh not_active IP Right Cessation
-
2018
- 2018-08-22 CO CONC2018/0008763A patent/CO2018008763A2/es unknown
-
2021
- 2021-05-23 JP JP2021086571A patent/JP7201740B2/ja active Active
- 2021-06-22 AU AU2021204201A patent/AU2021204201B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516663A5 (enExample) | ||
| JP2019513005A5 (enExample) | ||
| JP2020191862A5 (enExample) | ||
| JP2020198875A5 (enExample) | ||
| JP2021101700A5 (enExample) | ||
| JP2019536426A5 (enExample) | ||
| JP6639233B2 (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2019515650A5 (enExample) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2019502360A5 (enExample) | ||
| JP2019511214A5 (enExample) | ||
| JP2024099580A5 (enExample) | ||
| JP2020516681A5 (enExample) | ||
| HRP20201281T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma | |
| JP2019520038A5 (enExample) | ||
| JP2019515653A5 (enExample) | ||
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| HRP20210698T1 (hr) | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma | |
| JP2020506690A5 (enExample) | ||
| JP2019506838A5 (enExample) | ||
| JP2018536383A5 (enExample) | ||
| JP2016501829A5 (enExample) | ||
| JP2011520436A5 (enExample) | ||
| FI3388075T3 (fi) | Uusia peptidejä ja peptidien yhdistelmiä käytettäviksi immunoterapiaan erilaisia syöpiä vastaan | |
| AR110857A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |